<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Arthritis &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/arthritis/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>Starting rituximab with methotrexate has benefits in early RA</title>
		<link>http://www.thedoctorschannel.com/view/starting-rituximab-with-methotrexate-has-benefits-in-early-ra-2/</link>
		<pubDate>Fri, 24 Dec 2010 00:50:00 +0000</pubDate> 
				<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[Arthritis Care & Research]]></category>
		<category><![CDATA[Dr. William Rigby]]></category>
		<category><![CDATA[early active rheumatoid arthritis]]></category>
		<category><![CDATA[methotrexate]]></category>
		<category><![CDATA[MTX]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Rituximab]]></category>
		<category><![CDATA[TNF]]></category>
		<category><![CDATA[tumor necrosis factor]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/starting-rituximab-with-methotrexate-has-benefits-in-early-ra-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – When patients with early active rheumatoid arthritis (RA) start rituximab along with methotrexate (MTX), they have significantly better physical function and health-related quality of life a year later than if they had taken MTX alone, a new study shows. Rituximab is indicated for use in combination with MTX in patients -]]></description>
		
			<media:content duration="1:26" medium="video">
		<media:title><![CDATA[Starting rituximab with methotrexate has benefits in early RA]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – When patients with early active rheumatoid arthritis (RA) start rituximab along with methotrexate (MTX), they have significantly better physical function and health-related quality of life a year later than if they had taken MTX alone, a new study shows. Rituximab is indicated for use in combination with MTX in patients -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/starting-rituximab-with-methotrexate-has-benefits-in-early-ra-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3971.jpg"/>
	<media:keywords><![CDATA[Arthritis Care &amp; Research,Dr. William Rigby,early active rheumatoid arthritis,methotrexate,MTX,RA,Rituximab,TNF,tumor necrosis factor]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Abatacept effective for psoriatic arthritis</title>
		<link>http://www.thedoctorschannel.com/view/abatacept-effective-for-psoriatic-arthritis-2/</link>
		<pubDate>Fri, 24 Dec 2010 00:29:00 +0000</pubDate> 
				<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[abatacept]]></category>
		<category><![CDATA[Arthritis & Rheumatism]]></category>
		<category><![CDATA[Dr. Philip Mease]]></category>
		<category><![CDATA[PSA]]></category>
		<category><![CDATA[psoriatic arthritis]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/abatacept-effective-for-psoriatic-arthritis-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – The selective T-cell co-stimulation modulator abatacept safely and effectively treats psoriatic arthritis (PsA) in many patients, according to a report in the December 2nd online issue of Arthritis &#038; Rheumatism. “Abatacept yields moderate effectiveness for treating the arthritis component of PsA, and the safety profile is reasonably good,” Dr. Philip -]]></description>
		
			<media:content duration="1:41" medium="video">
		<media:title><![CDATA[Abatacept effective for psoriatic arthritis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – The selective T-cell co-stimulation modulator abatacept safely and effectively treats psoriatic arthritis (PsA) in many patients, according to a report in the December 2nd online issue of Arthritis &#038; Rheumatism. “Abatacept yields moderate effectiveness for treating the arthritis component of PsA, and the safety profile is reasonably good,” Dr. Philip -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/abatacept-effective-for-psoriatic-arthritis-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3968.jpg"/>
	<media:keywords><![CDATA[abatacept,Arthritis &amp; Rheumatism,Dr. Philip Mease,PSA,psoriatic arthritis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>No clear role for MRI in rheumatoid arthritis</title>
		<link>http://www.thedoctorschannel.com/view/no-clear-role-for-mri-in-rheumatoid-arthritis-2/</link>
		<pubDate>Thu, 23 Dec 2010 02:34:00 +0000</pubDate> 
				<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Radiology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[Arthritis Care & Research]]></category>
		<category><![CDATA[Dr. Lisa G. Suter]]></category>
		<category><![CDATA[MRI]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[rheumatoid arthritis]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/no-clear-role-for-mri-in-rheumatoid-arthritis-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Current data do not support the widespread use of MRI for the diagnosis and prognosis of rheumatoid arthritis (RA), researchers conclude in a report published November 17th online in Arthritis Care &#038; Research. “I do not think our findings suggest MRI has no role in diagnosing or prognosticating RA, but -]]></description>
		
			<media:content duration="1:16" medium="video">
		<media:title><![CDATA[No clear role for MRI in rheumatoid arthritis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Current data do not support the widespread use of MRI for the diagnosis and prognosis of rheumatoid arthritis (RA), researchers conclude in a report published November 17th online in Arthritis Care &#038; Research. “I do not think our findings suggest MRI has no role in diagnosing or prognosticating RA, but -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/no-clear-role-for-mri-in-rheumatoid-arthritis-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3967.jpg"/>
	<media:keywords><![CDATA[Arthritis Care &amp; Research,Dr. Lisa G. Suter,MRI,RA,rheumatoid arthritis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Low-dose naproxen should not be administered along with aspirin</title>
		<link>http://www.thedoctorschannel.com/view/low-dose-naproxen-should-not-be-administered-along-with-aspirin-2/</link>
		<pubDate>Mon, 20 Dec 2010 22:33:00 +0000</pubDate> 
				<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Patient Education]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[Arthritis & Rheumatism]]></category>
		<category><![CDATA[aspirin]]></category>
		<category><![CDATA[Dr. Paola Patrignani]]></category>
		<category><![CDATA[Low-dose naproxen]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/low-dose-naproxen-should-not-be-administered-along-with-aspirin-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Low-dose naproxen given close to the dosing of aspirin interferes with aspirin’s antiplatelet effects, according to a report in the November 23rd online Arthritis &#038; Rheumatism. “The results of this experiment clearly showed that the administration of naproxen given 2 hours before or after aspirin reduced the capacity of aspirin -]]></description>
		
			<media:content duration="1:23" medium="video">
		<media:title><![CDATA[Low-dose naproxen should not be administered along with aspirin]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Low-dose naproxen given close to the dosing of aspirin interferes with aspirin’s antiplatelet effects, according to a report in the November 23rd online Arthritis &#038; Rheumatism. “The results of this experiment clearly showed that the administration of naproxen given 2 hours before or after aspirin reduced the capacity of aspirin -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/low-dose-naproxen-should-not-be-administered-along-with-aspirin-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3956.jpg"/>
	<media:keywords><![CDATA[Arthritis &amp; Rheumatism,aspirin,Dr. Paola Patrignani,Low-dose naproxen]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Hydroxychloroquine improves lipid profiles in rheumatoid arthritis patients</title>
		<link>http://www.thedoctorschannel.com/view/hydroxychloroquine-improves-lipid-profiles-in-rheumatoid-arthritis-patients-2/</link>
		<pubDate>Wed, 08 Dec 2010 00:12:00 +0000</pubDate> 
				<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[Arthritis Care & Research]]></category>
		<category><![CDATA[cardiovascular disease]]></category>
		<category><![CDATA[Cholesterol]]></category>
		<category><![CDATA[Dr. Androniki Bili]]></category>
		<category><![CDATA[hydroxychloroquine]]></category>
		<category><![CDATA[rheumatoid arthritis]]></category>
		<category><![CDATA[triglycerides]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/hydroxychloroquine-improves-lipid-profiles-in-rheumatoid-arthritis-patients-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Hydroxychloroquine may reduce the heightened risk of cardiovascular disease in patients with rheumatoid arthritis. Use of hydroxychloroquine to treat rheumatoid arthritis is associated with reductions in cholesterol and triglycerides, a team with the Geisinger Health System in Danville, Pennsylvania has shown. Writing in Arthritis Care &#038; Research online November 15, -]]></description>
		
			<media:content duration="1:30" medium="video">
		<media:title><![CDATA[Hydroxychloroquine improves lipid profiles in rheumatoid arthritis patients]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Hydroxychloroquine may reduce the heightened risk of cardiovascular disease in patients with rheumatoid arthritis. Use of hydroxychloroquine to treat rheumatoid arthritis is associated with reductions in cholesterol and triglycerides, a team with the Geisinger Health System in Danville, Pennsylvania has shown. Writing in Arthritis Care &#038; Research online November 15, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/hydroxychloroquine-improves-lipid-profiles-in-rheumatoid-arthritis-patients-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3906.jpg"/>
	<media:keywords><![CDATA[Arthritis Care &amp; Research,cardiovascular disease,Cholesterol,Dr. Androniki Bili,hydroxychloroquine,rheumatoid arthritis,triglycerides]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>An Option for Osteoarthritis Treatment</title>
		<link>http://www.thedoctorschannel.com/view/an-option-for-osteoarthritis-treatment-2/</link>
		<pubDate>Tue, 07 Dec 2010 03:49:00 +0000</pubDate> 
				<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Information from Industry]]></category>
		<category><![CDATA[Orthopedics]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[Dore]]></category>
		<category><![CDATA[hcp]]></category>
		<category><![CDATA[osteoarthritis]]></category>
		<category><![CDATA[rheumatology]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/an-option-for-osteoarthritis-treatment-2/</guid>
		<description><![CDATA[p.v {padding-bottom:12px;}li.v {padding-bottom:12px;} Robin K. Dore, MD, a rheumatologist and clinical professor of medicine at the David Geffen School of Medicine at the University of California, Los Angeles and in private practice in Tustin, CA, discusses the burden of osteoarthritis in the United States and a treatment option, VIMOVO, which combines prescription-strength enteric-coated naproxen with -]]></description>
		
			<media:content duration="13:08" medium="video">
		<media:title><![CDATA[An Option for Osteoarthritis Treatment]]></media:title>
	<media:description><![CDATA[p.v {padding-bottom:12px;}li.v {padding-bottom:12px;} Robin K. Dore, MD, a rheumatologist and clinical professor of medicine at the David Geffen School of Medicine at the University of California, Los Angeles and in private practice in Tustin, CA, discusses the burden of osteoarthritis in the United States and a treatment option, VIMOVO, which combines prescription-strength enteric-coated naproxen with -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/an-option-for-osteoarthritis-treatment-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3904.jpg"/>
	<media:keywords><![CDATA[Dore,hcp,osteoarthritis,rheumatology]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Tocilizumab effective for rheumatoid arthritis when methotrexate insufficient</title>
		<link>http://www.thedoctorschannel.com/view/tocilizumab-effective-for-rheumatoid-arthritis-when-methotrexate-insufficient-2/</link>
		<pubDate>Tue, 07 Dec 2010 02:12:00 +0000</pubDate> 
				<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Orthopedics]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[Arthritis & Rheumatism]]></category>
		<category><![CDATA[Dr. Joel L. Kremer]]></category>
		<category><![CDATA[IL-6 receptor-blocking monoclonal antibody tocilizumab]]></category>
		<category><![CDATA[methotrexate]]></category>
		<category><![CDATA[rheumatoid arthritis]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/tocilizumab-effective-for-rheumatoid-arthritis-when-methotrexate-insufficient-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; The IL-6 receptor-blocking monoclonal antibody tocilizumab inhibits joint damage in patients with rheumatoid arthritis that is not adequately controlled with methotrexate, according to study results reported in the November 19th online issue of Arthritis &#038; Rheumatism. In January this year, the US Food and Drug Administration approved tocilizumab (Actemra/RoActemra; Roche), -]]></description>
		
			<media:content duration="1:34" medium="video">
		<media:title><![CDATA[Tocilizumab effective for rheumatoid arthritis when methotrexate insufficient]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; The IL-6 receptor-blocking monoclonal antibody tocilizumab inhibits joint damage in patients with rheumatoid arthritis that is not adequately controlled with methotrexate, according to study results reported in the November 19th online issue of Arthritis &#038; Rheumatism. In January this year, the US Food and Drug Administration approved tocilizumab (Actemra/RoActemra; Roche), -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/tocilizumab-effective-for-rheumatoid-arthritis-when-methotrexate-insufficient-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3903.jpg"/>
	<media:keywords><![CDATA[Arthritis &amp; Rheumatism,Dr. Joel L. Kremer,IL-6 receptor-blocking monoclonal antibody tocilizumab,methotrexate,rheumatoid arthritis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Doxycycline’s anti-osteoarthritis effect reduced in bowlegged women</title>
		<link>http://www.thedoctorschannel.com/view/doxycyclines-anti-osteoarthritis-effect-reduced-in-bowlegged-women/</link>
		<pubDate>Thu, 10 Jun 2010 18:07:00 +0000</pubDate> 
				<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Orthopedics]]></category>
		<category><![CDATA[Patient Education]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[bowlegged]]></category>
		<category><![CDATA[doxycycline]]></category>
		<category><![CDATA[malaligned]]></category>
		<category><![CDATA[neutrally aligned]]></category>
		<category><![CDATA[non-varus]]></category>
		<category><![CDATA[OA]]></category>
		<category><![CDATA[osteoarthritis]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/doxycyclines-anti-osteoarthritis-effect-reduced-in-bowlegged-women/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; The extent to which doxycycline slows the progression of knee osteoarthritis (OA) is not the same in neutrally aligned (non-varus) and malaligned (varus, or &#8220;bowlegged&#8221;) knees, according to a post hoc analysis of a randomized controlled trial. &#8220;Varus malalignment negated the slowing of structural progression of medial compartment OA by -]]></description>
		
			<media:content duration="1:45" medium="video">
		<media:title><![CDATA[Doxycycline’s anti-osteoarthritis effect reduced in bowlegged women]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; The extent to which doxycycline slows the progression of knee osteoarthritis (OA) is not the same in neutrally aligned (non-varus) and malaligned (varus, or &#8220;bowlegged&#8221;) knees, according to a post hoc analysis of a randomized controlled trial. &#8220;Varus malalignment negated the slowing of structural progression of medial compartment OA by -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/doxycyclines-anti-osteoarthritis-effect-reduced-in-bowlegged-women/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3331.jpg"/>
	<media:keywords><![CDATA[bowlegged,doxycycline,malaligned,neutrally aligned,non-varus,OA,osteoarthritis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>MRI aids early diagnosis of ankylosing spondylitis</title>
		<link>http://www.thedoctorschannel.com/view/mri-aids-early-diagnosis-of-ankylosing-spondylitis-2/</link>
		<pubDate>Mon, 07 Jun 2010 19:02:00 +0000</pubDate> 
				<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Orthopedics]]></category>
		<category><![CDATA[Patient Education]]></category>
		<category><![CDATA[Radiology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Rheumatology]]></category>
		<category><![CDATA[ASAS]]></category>
		<category><![CDATA[back pain]]></category>
		<category><![CDATA[MRI]]></category>
		<category><![CDATA[spondyloarthritis]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/mri-aids-early-diagnosis-of-ankylosing-spondylitis-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Magnetic resonance imaging (MRI) can help differentiate spondyloarthritis from nonspecific back pain, investigators report in the May 23rd online issue of Arthritis &#038; Rheumatism. “In spring 2009, MRI was accepted by the international research organization on spondyloarthritis (ASAS) as equivalent to X-ray” for diagnosis, lead author Dr. Ulrich Weber told -]]></description>
		
			<media:content duration="1:41" medium="video">
		<media:title><![CDATA[MRI aids early diagnosis of ankylosing spondylitis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Magnetic resonance imaging (MRI) can help differentiate spondyloarthritis from nonspecific back pain, investigators report in the May 23rd online issue of Arthritis &#038; Rheumatism. “In spring 2009, MRI was accepted by the international research organization on spondyloarthritis (ASAS) as equivalent to X-ray” for diagnosis, lead author Dr. Ulrich Weber told -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/mri-aids-early-diagnosis-of-ankylosing-spondylitis-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3317.jpg"/>
	<media:keywords><![CDATA[ASAS,back pain,MRI,spondyloarthritis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Adalimumab eases sciatica enough to avoid surgery</title>
		<link>http://www.thedoctorschannel.com/view/adalimumab-eases-sciatica-enough-to-avoid-surgery-2/</link>
		<pubDate>Wed, 28 Apr 2010 22:47:00 +0000</pubDate> 
				<category><![CDATA[Anesthesiology]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Emergency Medicine]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Neurology & Neurosurgery]]></category>
		<category><![CDATA[Orthopedics]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[adalimumab]]></category>
		<category><![CDATA[alpha inhibitor]]></category>
		<category><![CDATA[analgesia]]></category>
		<category><![CDATA[herniation]]></category>
		<category><![CDATA[TNF]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/adalimumab-eases-sciatica-enough-to-avoid-surgery-2/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; The TNF alpha inhibitor adalimumab provides minor analgesia in patients with radicular pain due to lumbar disc herniation, but prompts a major reduction in the need for surgery, Swiss researchers report in an April 6th online paper in Arthritis and Rheumatism. &#8220;Our study showed that a short course of adalimumab -]]></description>
		
			<media:content duration="1:52" medium="video">
		<media:title><![CDATA[Adalimumab eases sciatica enough to avoid surgery]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; The TNF alpha inhibitor adalimumab provides minor analgesia in patients with radicular pain due to lumbar disc herniation, but prompts a major reduction in the need for surgery, Swiss researchers report in an April 6th online paper in Arthritis and Rheumatism. &#8220;Our study showed that a short course of adalimumab -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/adalimumab-eases-sciatica-enough-to-avoid-surgery-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/06/3190.jpg"/>
	<media:keywords><![CDATA[adalimumab,alpha inhibitor,analgesia,herniation,TNF]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
